Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYB1907 in Advanced Solid Tumors
NCT05821595Phase 1Unknown
- Sponsor
- Jemincare
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of JYB1907 in solid tumor (6 arms), sponsored by Jemincare. Primary endpoint: Adverse events. Status: unknown.
02
Drugs
JYB1907
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05821595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821595.